HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U.S. Spending On Nanotech Research Questioned With Goods Flooding Market

This article was originally published in The Rose Sheet

Executive Summary

Europe is committing nearly twice as many dollars to nanotechnology risk research as the United States; meanwhile, consumer products engineered with materials on the nano scale are reaching the market at a rate of 3 to 4 per week, according to the Project on Emerging Nanotechnologies

You may also be interested in...



Informed Consumer Is Confident Consumer When It Comes To Nanotech – PEN

A more concerted effort is needed from industry and government to educate the public about nanotechnology, which almost half of U.S. adults say they have heard nothing about, according to the Project on Emerging Nanotechnologies and a new report from Peter D. Hart Research Associates

Informed Consumer Is Confident Consumer When It Comes To Nanotech – PEN

A more concerted effort is needed from industry and government to educate the public about nanotechnology, which almost half of U.S. adults say they have heard nothing about, according to the Project on Emerging Nanotechnologies and a new report from Peter D. Hart Research Associates

FDA Curious About Safety Measures Taken By Cosmetic Firms Using Nanotech

At an upcoming public meeting FDA will seek perspective from personal-care manufacturers that work with nano-scale materials on the measures taken to ensure that products containing such materials are safe

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015413

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel